A pilot study to test the effects of a single microdose of ayahuasca alkaloids on blood pathology of neurotransmitters and inflammation marker levels, safety observations, and mood self-efficacy in healthy adults

This open-label pilot study (n=5) aims to assess the feasibility of a single microdose of ayahuasca alkaloids (30mg) on neurotransmitter and inflammation marker levels, safety observations, and mood self-efficacy in healthy adults.

Conducted by Biochem Industries Pty Ltd in Australia, the study involves administering a single dose of 30 mg ayahuasca alkaloids and 1.31 g l-epicatechin cyclodextrin complex dissolved in water and propylene glycol.

Participants, aged 25-60, will be closely monitored for safety measures, including blood pressure, heart rate, and oxygen saturation. The study hypothesis is that the microdose will affect neurotransmitter levels and mood positively. Mr. Victor Chiruta from Independent Food and Therapeutic Assessor Ltd is the principal investigator. The study aims to recruit four participants and is expected to be conducted from May to June 2023. No individual participant data will be shared.

Topic Healthy Subjects Microdosing
Compound Ayahuasca
Country Australia
Visit trial

Trial Details



Trial Number

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.